Neumirna Therapeutics is a biotechnology company based in Copenhagen, Denmark, focused on developing RNA-based therapies to treat neurological diseases. Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen, the company is dedicated to transforming patients' lives through the modulation of microRNAs with therapies that have the potential to address the root cause of diseases. The company operates from multiple locations, including Copenhagen, Basel, and Boston.
The company's pioneering drug discovery platform enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson's disease (PD). As of April 2026, the company has 19 employees. In January 2025, Neumirna secured €20M in Series A financing, co-led by Angelini Ventures and Invivo Partners.
Recent leadership news
Ellen K. Donnelly, Ph.D. was appointed Chief Executive Officer in September 2025, bringing more than 20 years of leadership in neuroscience and rare diseases. In May 2026, Dr. Ferenc Tracik was appointed Chief Medical Officer.
Facts compiled by Executive Moves from publicly available news and press releases on 26 May 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Neumirna Therapeutics team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
